Vaccine avertable AMR burden globally and by WHO region
| WHO region | Vaccine avertable deaths (median and 95% UI) | Vaccine avertable DALYs (median and 95% UI) | ||
| Associated with resistance | Attributable to resistance | Associated with resistance | Attributable to resistance | |
| Africa | 166 105 (154 785–180 343) | 44 745 (40 658–49 196) | 12 311 693 (11 333 145–13 343 956) | 3 092 513 (2 783 222–3 396 579) |
| Americas | 32 901 (30 020-35 892) | 8824 (7 949–9 939) | 1 153 608 (1 062 629–1 250 636) | 295 226 (269 907–321 201) |
| Eastern Mediterranean | 61 060 (56 445–66 784) | 18 105 (16 426–20 194) | 4 100 742 (3 742 727–4 559 594) | 1 133 518 (1 023 025–1 258 309) |
| Europe | 32 218 (29 145–37 168) | 9721 (8 646–11 126) | 944 991 (875 082–1 031 180) | 291 308 (265 281–325 272) |
| South-East Asia | 162 699 (147 461–179 566) | 54 989 (47 336–64 667) | 7 523 796 (6 770 514–8 458 311) | 2 289 200 (2 014 438–2 684 501) |
| Western Pacific | 58 701 (52 392–67 736) | 16 569 (14 593–19 491) | 1 933 726 (1 778 575–2 113 470) | 508 474 (466 317–566 236) |
| Global | 514 631 (491 550–540 336) | 153 009 (144 253–165 008) | 27 978 617 (26 626 506–29 377 853) | 7 620 837 (7 133 393–8 046 001) |
The estimates (median and 95% UIs) for vaccine avertable disease burden attributable to and associated with bacterial AMR in 2019 is presented in terms of deaths and DALYs avertable by vaccination in the baseline scenario.